Table 3.
Comparison of COVID-19 vaccines in induction of IgG antibody against SARS-CoV-2 spike protein and their side effects in HCWs
| Anti-spike antibody | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-vaccination | ≥3 weeks post first vaccination | ≥3 weeks post second vaccination | |||||||
| Mean ± s.d. | Sputnik | AstraZeneca | Sinopharm | P-value | Sputnik | AstraZeneca | Sinopharm | P-value | |
| Antibody ratio | 2.14 ± 2.8 | 7.1 ± (−3.5) | 14 ± 91 | 5.3 ± 2.5 | 14.5 ± 112 | 4.2 ± 2.5 | 3.7 ± 2 | ||
| Confirmed infection | 352/799 (44%) | 5/175 (2.8%) | 17/180 (9.4%) | 0/45 (0) | 0.005 | 12/241 (5%) | 2/16 (12.5%) | 1/6 (16.6%) | 0.2 |
| BMI | |||||||||
| ELISA positive | 43 ± 8.5 | ||||||||
| ELISA negative | 41.4 ± 8.3 | ||||||||
| Vaccine side effects | |||||||||
| Fever | 61/174, 35% | 108/181, 59.6% | 1/45, 2.2% | 0.001 | 34/97, 35% | 11/19, 57.8% | 1/8, 12.5% | 0.056 | |
| Myalgia/arthralgia | 92/174, 52.8% | 131/180, 72.7% | 5/45, 11.1% | 0.0001 | 123/242, 86.6% | 2/13, 15.3% | 0/6, 0 | 0.002 | |
| Malaise | 92/174, 52.8% | 123/181, 67.9% | 3/45, 6.6% | 0.0001 | 117/242, 48.3% | 2/13, 15.3% | 0/6, 0 | 0.005 | |
| Chills | 50/174, 28.7% | 110/181, 60.7% | 1/45, 2.2% | 0.0001 | 84/242, 34.7% | 3/13, 23% | 0/6, 0 | 0.15 | |
| Headache | 59/174, 33.9% | 82/181, 45.3% | 4/45, 8.8% | 0.0001 | 75/242, 31% | 2/13, 15.3% | 0/6, 0 | 0.13 | |
| Hospitalisation | 1/269, 0.3% | 12/238, 5% | 0/78, 0 | 0.0006 | 8/358, 2.2% | 0/64, 0 | 0/0 | 0.3 | |
| Receiving of COVID-19 drugs | 1 | 2 | 0 | 7 | 0 | 0 | |||
Significant p values are shown in bold.